Processa Pharmaceuticals, Inc. (PCSA): Nasdaq/NYSE listing notice — Processa receives Nasdaq bid-price deficiency notice; 180 days to regain compliance

Processa Pharmaceuticals, Inc.

Nasdaq notified Processa that common stock bid price closed below $1.00 for 30 consecutive business days.
Company has until August 4, 2025 to regain compliance by closing at $1.00 or more for 10 consecutive days.
If not compliant by deadline, may qualify for a second 180-day period or face potential delisting.
Stock continues trading under symbol PCSA on Nasdaq Capital Market during cure period.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Processa Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

February 4, 2025, Processa Pharmaceuticals, Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company t

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Processa Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

February 4, 2025, Processa Pharmaceuticals, Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the previous 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”). The Notice has no effect at this time on the Company’s common stock, which continues to trade on The Nasdaq

View on SEC.gov

Browse all listing & compliance notices →

Processa Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-005633

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.